Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer (ABC)

This study has been completed.
Sponsor:
Collaborators:
Genentech, Inc.
Celgene Corporation
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00479674
First received: May 25, 2007
Last updated: January 29, 2015
Last verified: January 2015
Results First Received: December 9, 2014  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Condition: Breast Cancer
Interventions: Drug: Abraxane
Drug: Bevacizumab
Drug: Carboplatin

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Abraxane, Carboplatin, Bevacizumab

Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15

Abraxane: 100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..

Bevacizumab: 10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.

Carboplatin: area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.


Participant Flow:   Overall Study
    Abraxane, Carboplatin, Bevacizumab  
STARTED     41  
COMPLETED     0  
NOT COMPLETED     41  
Adverse Event                 18  
Withdrawal by Subject                 6  
Physician Decision                 14  
none provided                 3  



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Abraxane, Carboplatin, Bevacizumab

Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15

Abraxane: 100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..

Bevacizumab: 10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.

Carboplatin: area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.


Baseline Measures
    Abraxane, Carboplatin, Bevacizumab  
Number of Participants  
[units: participants]
  41  
Age  
[units: years]
Mean (Standard Deviation)
  50  (11)  
Gender  
[units: participants]
 
Female     41  
Male     0  
Race (NIH/OMB)  
[units: participants]
 
American Indian or Alaska Native     0  
Asian     0  
Native Hawaiian or Other Pacific Islander     0  
Black or African American     12  
White     25  
More than one race     0  
Unknown or Not Reported     4  
Region of Enrollment  
[units: participants]
 
United States     41  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Best Clinical Response Expressed as Percentage of Participants Treated With Combination Regimen of Weekly Abraxane® and Carboplatin Plus Biweekly Bevacizumab to Treat Women With Stage IV or Inoperable Stage III "Triple Negative" Metastatic Breast Cancer.   [ Time Frame: 5 years ]

2.  Secondary:   Median Proportion Progression-free as Estimated by Kaplan-Meier Methods   [ Time Frame: 5 years ]

3.  Secondary:   To Evaluate Sequential Plasma Samples for Presence of Selected Angiogenic Markers   [ Time Frame: 18 months ]

4.  Secondary:   to Determine if Apolipoprotein Alleles (Apo-E) Correlate With Treatment-related Neuropathy   [ Time Frame: 18 months ]

5.  Secondary:   to Determine if SPARC Expression in Breast Tumors Predicts Progression-free Survival (PFS)   [ Time Frame: 18 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.


Results Point of Contact:  
Name/Title: Dr. Kimberly Blackwell
Organization: Duke University Medical Center
phone: 919-668-1748
e-mail: black034@duke.edu


No publications provided


Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT00479674     History of Changes
Other Study ID Numbers: Pro00014837, AVF3962s
Study First Received: May 25, 2007
Results First Received: December 9, 2014
Last Updated: January 29, 2015
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration